Do you want to change careers? Are you absolutely sure?
From my own career change to the stories I hear from my clients and workshop students, often we think we want to change careers when the problem is our work environment instead. If you find yourself stuck, unsure what to do next, or t
Best Biotech ETF: The biotech sector has been greatly outperforming the broader markets over the past three months. In fact, the Nasdaq Biotechnology sector has climbed more than 14% since June, while the Dow is up just 2% in that time.
And we see those biotech gains continuing from here. That’s why we’re bringing readers the best biotech ETF to buy now.
Stocks jumped back from modest declines that came late in Thursday’s trading session, and by the closing bell, both the Dow Jones Industrial Average(DJINDICES:^DJI) and the S&P 500 (SNPINDEX:^GSPC) indexes had posted tiny gains.
May 1, 2017: Markets opened higher on Monday following an agreement that keeps the federal government solvent through the end of September. Blue chips have shown very little gain today, with telecom and utilities performing worst and tech and financials performing best. WTI crude oil for June delivery settled at $48.84 a barrel, down 1% on the day. June gold also dropped 1% for the day to settle....More>>>
According to the GuruFocus All-in-One Screener, several gurus are focusing on stocks whose Peter Lynch fair values are far above the current prices. The following stocks are trading with wide margins of safety and have positive performances over the past 12 months.
Wi-LAN Inc. (WILN) is trading around $1.83 per share. The Peter Lynch value gives the stock a fair price of $2.3 so the stock....More>>>
Gainers Loxo Oncology Inc (NASDAQ: LOXO) rose 32.7 percent to $65.00 in pre-market trading after the company reported that larotrectinib trial demonstrated 76 percent confirmed objective response rate. Dynavax Technologies Corporation (NASDAQ: DVAX) shares rose 22 percent to $7.20 in the pre-market trading session after the company on Friday presented updated data for SD-101 in combination....More>>>
The candy maker said Tuesday that it’ll cut its global workforce by about 15%, which likely amounts to about 2,700 people. The company employs about 18,000 people worldwide, according to public filings last December.
The cuts will be “driven primarily by its hourly headcount outside of the United States,” the company....More>>>
IsQUALCOMM, Inc. stock a good long-term buy now? Flickr
Shares of San Diego, California-based smartphone chipmakerQUALCOMM, Inc. (NASDAQ:QCOM)are up by more than 9% in the last one month. QCOM stock seems to be in recovery mode after the lawsuits driven sell-off in January. To add to that Qualcomm had postedmixed Q1-2017 earningswhich further spooked investors. Investors have been....More>>>
History could portend a bad omen for President-elect Donald Trump: recessions are more common under Republican presidents.
Every Republican president since Teddy Roosevelt in the early 1900’s endured a recession in their first term, according to an analysis from Sam Stovall, chief investment strategist atstock research firm CFRA.Four Republican presidents suffered through two recessions....More>>>
The biopharma and drug supply chain sectors outperformed the market last week, even as Trump administration officials pressed the president's blueprint to lower drug prices, with tough rhetoric for drugmakers and public shaming of pharmaceutical firms for supposedly blocking competition.
Since March 2009, the stock market has been virtually unstoppable. At one point in January 2018, all three major indexes -- the Dow Jones Industrial Average, S&P 500, and Nasdaq-- had essentially quadrupled from their Great Recession lows.
NanoString Technologies (NASDAQ: NSTG) is one of 91 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its competitors? We will compare NanoString Technologies to related businesses based on the strength of its earnings, p
Geron Corporation (NASDAQ:GERN), a clinical-stage cancer company, has grabbed the attention of growth investors due to its enormous upside potential. The short version of the story is that Geron is awaiting a critical continuation decision by partner Johnson & Johnson (NYSE:JNJ) in regards t
The average stock in the Nasdaq 100 is up just over 3% year to date. Using snapshots from our popular Trend Analyzer tool, below is a look at the best and worst performing stocks in the Nasdaq 100 so far in 2018.
At the top of the list is Netflix (NASDAQ:NFLX) with a year-to-date gain of